Ken Griffin Blueprint Medicines Corp Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 162,400 shares of BPMC stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

162,400

Previous 118,800 36.7%

Holding current value

$14.4 Million

Previous $11.3 Million 55.32%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $3.34 Million - $4.27 Million	39,211 New	39,211 $4.23 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $17,935 - $37,878	408 Added 0.43%	95,325 $8.79 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $753,307 - $1.06 Million	-16,062 Reduced 14.47%	94,917 $4.77 Million
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $7.51 Million - $11.8 Million	-178,076 Reduced 61.61%	110,979 $7.01 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $2.49 Million - $3.28 Million	65,633 Added 29.38%	289,055 $13 Million
Q4 2022 Feb 14, 2023	SELL	$41.06 - $66.48 $3.34 Million - $5.41 Million	-81,365 Reduced 26.7%	223,422 $9.79 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $11.8 Million - $18.3 Million	235,528 Added 340.07%	304,787 $20.1 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $16.5 Million - $25.6 Million	-365,480 Reduced 84.07%	69,259 $3.5 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $18.3 Million - $37.3 Million	338,425 Added 351.38%	434,739 $27.8 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $8.74 Million - $10.8 Million	92,741 Added 2595.61%	96,314 $10.3 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $79,360 - $107,280	980 Added 37.79%	3,573 $367,000
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $1.57 Million - $1.92 Million	-19,010 Reduced 88.0%	2,593 $228,000
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $4.44 Million - $6 Million	-48,188 Reduced 69.05%	21,603 $2.42 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $23.6 Million - $32.9 Million	-354,819 Reduced 83.56%	69,791 $6.47 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $1.22 Million - $1.7 Million	-21,457 Reduced 4.81%	424,610 $33.1 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $18.5 Million - $31.6 Million	384,208 Added 621.1%	446,067 $26.1 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $1.05 Million - $1.3 Million	-15,684 Reduced 20.23%	61,859 $4.96 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $1.08 Million - $1.51 Million	14,879 Added 23.74%	77,543 $5.7 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $1.35 Million - $1.79 Million	-18,326 Reduced 22.63%	62,664 $5.91 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $3.13 Million - $5.56 Million	64,201 Added 382.4%	80,990 $0
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $9.19 Million - $15 Million	-201,720 Reduced 92.32%	16,789 $905,000
Q3 2018 Nov 13, 2018	BUY	$58.91 - $78.32 $10.2 Million - $13.6 Million	173,614 Added 386.71%	218,509 $0
Q2 2018 Aug 10, 2018	BUY	$60.96 - $101.18 $2.24 Million - $3.72 Million	36,779 Added 453.17%	44,895 $0
Q1 2018 May 11, 2018	SELL	$73.28 - $102.95 $743,205 - $1.04 Million	-10,142 Reduced 55.55%	8,116 $744,000
Q4 2017 Feb 09, 2018	BUY	$62.91 - $88.32 $1.15 Million - $1.61 Million	18,258	18,258 $1.38 Million

Others Institutions Holding BPMC

# of Institutions

340

Shares Held

62M

Call Options Held

987K

Put Options Held

578K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.31B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account